Safety and Efficacy of Prophylactic Nanofiltered C1-inhibitor in Hereditary Angioedema
Authors:
- Bruce L. ZurawBZBruce L. Zuraw
- Ira KalfusIKIra Kalfus
- 1 September 2012
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Medicine
- Vol. 125 (9) , 938.e1-938.e7
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Hereditary AngioedemaNew England Journal of Medicine, 2008
- Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patientsAnnals of Allergy, Asthma & Immunology, 2008
- Hereditary angioedema: Safety of long-term stanozolol therapyJournal of Allergy and Clinical Immunology, 2007
- Hereditary Angioedema: The Clinical Syndrome and its Management in the United StatesImmunology and Allergy Clinics of North America, 2006
- Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedemaJournal of Allergy and Clinical Immunology, 2005
- Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyondJournal of Allergy and Clinical Immunology, 2004
- Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: Comparison of treated and untreated patientsJournal of Allergy and Clinical Immunology, 1997
- Hereditary and Acquired C1-Inhibitor DeficiencyMedicine, 1992
- Treatment of Hereditary Angioedema with DanazolNew England Journal of Medicine, 1976
- Epsilon Aminocaproic Acid Therapy of Hereditary Angioneurotic EdemaNew England Journal of Medicine, 1972